Orchid Chemicals & Pharmaceuticals Limited

Orchid Research Laboratories Limited

Ganapavarapu Veera Raghava Sharma

Sukunath Narayanan

Sriram K Rajagopal

Ravikumar Tadiparthi

Gopalan Balasubramanian

Virendra Kachhadia

Venkatesan Parameswaran

Shridhar Narayanan

Uma Ramachandran

Sanjeev Saxena

Sathya Narayana Thara

Venkatesan Janarthanam

Maruthikumar Narayanam

Sathyanarayana Gadde

Durairaj Peter Bhakiaraj

Gaddam Om Reddy

Sridharan Rajagopal

Akella Satya Surya Visweswara Srinivas

Sappanimuthu Thirunavukkarasu

Santosh Vishwakarma

Kilambi Narasimhan

Lavanya Andiappan

Om Reddy Gaddam

Saravanan Thirunavukkarasu

Narayanan Surendran

Lolaknath Santosh Vishwakarma

Visweswara Akella Satya Surya Srinivas

Kilambi Narsimhan

Thirunavukkarasu Sappanimuthu

Compounds of the formula (I), their derivatives, analogs, tautomeric forms, regioisomers, stereoisomers, polymorphs, solvates, intermediates, pharmaceutically acceptable salts, pharmaceutical compositions, N-oxides, metabolites and prodrugs thereof. These compounds are phosphodiesterase type 4 (PDE4) inhibitors. They are useful in the treatment of a variety of allergic or inflammatory diseases including asthma, COPD, chronic bronchitis, atopic dermatitis, allergic rhinitis, allergic conjunctivitis, vernal conjuctivitis, psoriasis, rheumatoid arthritis, ulcerative colitis, Crohn's disease, uveitis, NASH and lupus.

Heterocyclic compounds as phosphodiesterase inhibitors

Described are novel heterocyclic compounds of the general formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites and prodrugs thereof. These compounds are useful in the treatment of immunological diseases, inflammation, pain disorder, rheumatoid arthritis; osteoporosis; multiple myeloma; uveititis; acute and chronic myelogenous leukemia; atherosclerosis; cancer; cachexia; ischemic-induced cell damage; pancreatic beta cell destruction; osteoarthritis; rheumatoid spondylitis; gouty arthritis; inflammatory bowel disease; ARDS; psoriasis; Crohn's disease; allergic rhinitis; ulcerative colitis; anaphylaxis; contact dermatitis; muscle degeneration; asthma; COPD; bone resorption diseases; multiple sclerosis; sepsis; septic shock; toxic shock syndrome and fever. More particularly these compounds are useful as PDE4 inhibitors and are useful for treating PDE4 mediated diseases. 

Pyrimidine compounds and their uses

Novel heterocyclic compounds of the general formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites and prodrugs thereof are described. These compounds are useful in the treatment of immunological diseases, inflammation, pain disorder, rheumatoid arthritis; osteoporosis; multiple myeloma; uveititis; acute and chronic myelogenous leukemia; atherosclerosis; cancer; cachexia; ischemic-induced cell-damage; pancreatic beta cell destruction; osteoarthritis; rheumatoid spondylitis; gouty arthritis; inflammatory bowel disease; adult respiratory distress syndrome (ARDS); psoriasis; Crohn's disease; allergic rhinitis; ulcerative colitis; anaphylaxis; contact dermatitis; muscle degeneration; asthma; COPD; bone resorption diseases; multiple sclerosis; sepsis; septic shock; toxic shock syndrome and fever. More particularly these compounds are useful as PDE4 inhibitors, and useful for treating PDE4 mediated diseases. 

Heterocycles

Growing community of inventors

Vishakhapatnam, India

Ganapavarapu Veera Raghava Sharma